Target Validation Information
TTD ID	T65019
Target Name	Matrix metalloproteinase-14 (MMP-14)
Type of Target	Clinical trial
Drug Potency against Target	BMS 275291	Drug Info	IC50 = 40 nM	[10]
	2-(4-bromophenylsulfonamido)-N-hydroxyacetamide	Drug Info	IC50 = 360 nM	[8]
	2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide	Drug Info	IC50 = 70 nM	[8]
	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Drug Info	IC50 = 8300 nM	[7]
	Epigallocatechin gallate	Drug Info	IC50 = 6800 nM	[6]
	GM6001	Drug Info	IC50 = 5.2 nM	[5]
	IK-862	Drug Info	Ki = 15872 nM	[1]
	MMI270	Drug Info	IC50 = 23 nM	[4]
	N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide	Drug Info	IC50 = 210 nM	[8]
	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Drug Info	IC50 = 1300 nM	[7]
	SR-973	Drug Info	Ki = 1200 nM	[3]
	UK-356618	Drug Info	IC50 = 1900 nM	[2]
	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Drug Info	IC50 = 5400 nM	[7]
Action against Disease Model	PG-530742	Drug Info	Selective matrix metalloproteinase inhibition by PG-530742 (at doses 0.2 mg/kg to 3.5 mg/kg) attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure	[9]
References
REF 1	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
REF 2	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
REF 3	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
REF 4	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
REF 5	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
REF 6	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
REF 7	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
REF 8	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
REF 9	Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
REF 10	Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 2001 Dec 1;61(23):8480-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.